Form 4: Alto Neuroscience Director Acquires Stock Options

Alto Neuroscience, Inc. director Manji Husseini acquired 10,958 stock options with an exercise price of $24.63.

Summary

• Manji Husseini, a Director at Alto Neuroscience, Inc., acquired 10,958 stock options on May 12, 2026.
• The options have an exercise price of $24.63 and an expiration date of May 11, 2036.
• These options were granted under the company's Non-Employee Director Compensation Policy and do not require payment of consideration.
• The underlying shares are common stock.
• The options are set to vest on the earlier of the one-year anniversary of the grant date or the Issuer's next Annual Meeting following the grant date, contingent on continuous service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard compensation event for a director rather than a significant financial transaction or strategic announcement.

Positives

• Director acquisition of stock options can signal confidence in the company's future prospects.
• The options are granted under a formal compensation policy, indicating established governance practices.
• The vesting schedule aligns with continued service, incentivizing long-term commitment.

Negatives

• The filing only details the acquisition of options, not the exercise or sale of shares, so immediate financial impact is not yet realized.
• The exercise price of $24.63 is a benchmark that the stock price needs to exceed for the options to be profitable.

Risks

• The value of the stock options is subject to market fluctuations and the company's future performance.
• Failure to meet continuous service requirements could result in forfeiture of the options.
• The company's stock price may not reach the exercise price of $24.63, rendering the options worthless.

Future Outlook

The vesting schedule for the stock options is tied to the company's next Annual Meeting or a one-year anniversary, suggesting management's expectation of continued operations and potential for future value creation.

Industry Context

StockSavvy.ai notes that the granting of stock options to directors is a common practice in the biotechnology and neuroscience sectors, aligning executive incentives with shareholder value and long-term company growth.

Corporate Governance

Related Party Transactions

• Acquisition of stock options by Director Manji Husseini under the Non-Employee Director Compensation Policy.

Stakeholder Impact

• Shareholders: The issuance of options dilutes ownership slightly but also aligns director incentives with long-term shareholder value.
• Employees: May be seen as a positive sign of director commitment, potentially boosting morale.
• Management: Reinforces standard compensation practices for directors.

Next Steps

• The stock options will vest on the earlier of the one-year anniversary of the grant date or the Issuer's next Annual Meeting following the grant date, subject to continuous service.
• The options can be exercised up to their expiration date of May 11, 2036, provided they have vested.

Key Dates

Keywords

Alto Neuroscience, ANRO, Form 4, Stock Options, Director Compensation, Insider Trading, Securities, SEC Filing